Episode Details
Back to Episodes
Cannabis Industry: Global Growth Clashes With US Market Pressures and Oversupply Challenges
Published 1 month, 1 week ago
Description
In the past 48 hours, the cannabis industry shows mixed signals with regulatory progress, international expansion, and U.S. market pressures. Tilray Medical announced its largest medical cannabis portfolio expansion in Australia on March 19, adding Redecan extracts, flower, vapes, pastilles, and Good Supply flower to boost patient access in regulated channels[2][4]. This follows Tilrays recent BrewDog acquisitions targeting 1.2 billion dollars in consolidated revenue, signaling aggressive global growth amid prior quarters net revenue of 217.5 million dollars[2].
In the U.S., Virginias recreational sales bill advanced to Governor Spanbergers desk, eyeing a January 2027 market launch with a 6 percent flat tax plus local rates up to 3.5 percent, directing 40 percent of revenue to education and a reinvestment fund for small businesses[1][5]. This contrasts prior vetoes and aims to disrupt illicit markets, per a NORML study showing adult-use legalization significantly cuts unregulated sales[13]. However, Massachusetts faces oversupply woes, with growers urging a license freeze as excess cannabis drives down prices and threatens closures; regulators discussed this on March 18 without decision[3][15].
High Tide reported quarterly revenue of 178.3 million Canadian dollars but a net loss of 0.4 million, while The Cannabist Company extended noteholder forbearance[1]. Ohio hemp THC restrictions take effect March 20 after a referendum failed, tightening rules post-2023 legalization[1][11]. DEA data confirms legal cannabis does not increase youth use, countering critics[1].
Leaders like Tilray respond to challenges by diversifying internationally, unlike U.S. firms hit by 280E tax burdens potentially eased by pending Schedule III rescheduling[9]. Compared to last week, activity ramps up on product launches and bills versus quieter business filings. No major consumer shifts or supply disruptions reported, but oversupply signals price drops in saturated states. Overall, expansion abroad offsets domestic regulatory hurdles.(348 words)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI
In the U.S., Virginias recreational sales bill advanced to Governor Spanbergers desk, eyeing a January 2027 market launch with a 6 percent flat tax plus local rates up to 3.5 percent, directing 40 percent of revenue to education and a reinvestment fund for small businesses[1][5]. This contrasts prior vetoes and aims to disrupt illicit markets, per a NORML study showing adult-use legalization significantly cuts unregulated sales[13]. However, Massachusetts faces oversupply woes, with growers urging a license freeze as excess cannabis drives down prices and threatens closures; regulators discussed this on March 18 without decision[3][15].
High Tide reported quarterly revenue of 178.3 million Canadian dollars but a net loss of 0.4 million, while The Cannabist Company extended noteholder forbearance[1]. Ohio hemp THC restrictions take effect March 20 after a referendum failed, tightening rules post-2023 legalization[1][11]. DEA data confirms legal cannabis does not increase youth use, countering critics[1].
Leaders like Tilray respond to challenges by diversifying internationally, unlike U.S. firms hit by 280E tax burdens potentially eased by pending Schedule III rescheduling[9]. Compared to last week, activity ramps up on product launches and bills versus quieter business filings. No major consumer shifts or supply disruptions reported, but oversupply signals price drops in saturated states. Overall, expansion abroad offsets domestic regulatory hurdles.(348 words)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI